NEW YORK, NY / ACCESSWIRE / March 14, 2022 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.
Cerence Inc. (NASDAQ:CRNC)
CONTACT JAKUBOWITZ ABOUT CRNC:
https://claimyourloss.com/securities/cerence-inc-loss-submission-form/?id=24665&from=1
Class Period : February 8, 2021 - February 4, 2022
Lead Plaintiff Deadline : April 26, 2022
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the global semiconductor shortage had a materially negative impact on demand for Cerence's software licenses; (2) defendants masked the impact of the semiconductor shortage on demand for the Company's software licenses by pulling forward sales; and (3) as a result of the above, defendants' statements about Cerence's business, operations, and prospects were false and misleading and/or lacked a reasonable basis.
Cabaletta Bio, Inc. (NASDAQ:CABA)
CONTACT JAKUBOWITZ ABOUT CABA:
https://claimyourloss.com/securities/cabaletta-bio-inc-loss-submission-form/?id=24665&from=1
This lawsuit is on behalf of persons and entities that purchased or otherwise acquired: (a) Cabaletta common stock pursuant and/or traceable to documents issued in connection with the Company's initial public offering conducted on or about October 24, 2019; and/or (b) Cabaletta securities between October 24, 2019 and December 13, 2021, both dates inclusive.
Lead Plaintiff Deadline : April 29, 2022
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) top-line data of the Phase 1 Clinical Trial indicated that Cabaletta's lead product candidate, DSG3-CAART, had, among other things, worsened certain participants' disease activity scores and necessitated additional systemic medication to improve disease activity after DSG3-CAART infusion; (ii) accordingly, DSG3-CAART was not as effective as the Company had represented to investors; (iii) therefore, the Company had overstated DSG3-CAART's clinical and/or commercial prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Meta Platforms, Inc. (NASDAQ:FB)
CONTACT JAKUBOWITZ ABOUT FB:
https://claimyourloss.com/securities/meta-platforms-inc-loss-submission-form/?id=24665&from=1
Class Period : March 2, 2021 - February 2, 2022
Lead Plaintiff Deadline : May 9, 2022
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Apple's iOS privacy changes were having a material impact on Meta's ability to provide the kind of targeted advertising that its customers wanted and, as a result, customer ad spending was dropping precipitously; (2) Meta's mitigation efforts were either not properly implemented or ineffective; (3) measurement of ads was not accurate as mitigation efforts were failing; and (4) Meta did not have a plan in place to properly address the impact of the iOS privacy changes.
Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887
SOURCE : Jakubowitz Law